Umbilical Cord Stem Cells Therapies
This is a chart taken from Dr. David Steenblock’s excellent website on stem cell therapy, www.stemcelltherapies.org.
Find this page at www.stemcelltherapies.org/umresearch.htm
Umbilical cord stem cells can or soon will be able to:
1) Repair injuries to the heart muscle of heart attack victims.
2) Reduce the clinical symptoms of Parkinson's disease.
3) Improve the outcome of cancer patients.
4) Improve the quality of life in patients with Multiple Sclerosis.
5) Improve outcome for children with cerebral palsy.
6) Improve outcome for acute and chronic stroke patients.
7) Improve outcome for patients with acute and chronic traumatic brain injuries.
8) Improve outcome for those with muscular dystrophy
9) Improve outcome for those with Huntington's Disease
10) Reduce symptoms of Diabetes 1 and 2
11) Improve the symptoms in Autism Spectrum Disorder
12) Improve vision
13) Improve symptoms in Down Syndrome
14) Improve symptoms of Rheumatoid Arthritis
15) Improve symptoms in Amyotrophic Lateral Sclerosis (ALS)
16) Improve function in Spinal cord injury
17) Reduce symptoms in Epilepsy
18) Improve symptoms in sickle cell anemia
For further medical research, search PubMed for “umbilical cord stem cells” and a health condition of interest to you to see more summaries of the work being done.
Want detailed stem cell educational information? If so be sure to click below to learn about Human Umbilical Cord Stem Cells, What are Stem Cells, Why are they important and how can they be used as preventive therapies, also learn about different sources and types of stem cells, and how they are separated and processed.
CLICK HERE for: Detailed Stem Cell Educational page
Ready to get your treatment? Click here for Treatment Center information
Ready to order your treatment? CLICK HERE for our product page
Click here to join our FORUMS 
Skype us now
NEW Signup to our FREE monthly newsletter
We are dedicated to bringing stem cell healing therapies to the world NOW!
USA ONLY: The mesenchymal and umbilical cord blood stem cells used in this study are human cells, tissues, or cellular and tissue-based products (HCT/Ps) as defined in 21 CFR § 1271.3(d). Under 21 CFR Part 1271, HCT/Ps are not subject to licensure or IND requirements if certain criteria are met (21 CFR § 1271.10). These requirements include autologous use (use by the cell donor), or if used for other patients, the HCT/Ps must be “not more than minimally manipulated” and labeled for use for “homologous use only”. They may also not be used for a purpose requiring their “metabolic” activity. StemLab S.A. mesenchymal and umbilical cord stem cells shipped to the United States of America have not been “more than minimally manipulated”. StemLab S.A. labels and intends its cells which are used within the United States of America only for homologous and non-metabolic purposes. StemLab S.A. does not interfere with the practice of medicine by individual physicians who use StemLab products, and who may do so according to their own medical training and informed choice.
StemTech Labs is a Global Genius Trust company